Almirall S.A. (ALM) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.060x

Based on the latest financial reports, Almirall S.A. (ALM) has a cash flow conversion efficiency ratio of 0.060x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€88.75 Million ≈ $103.76 Million USD) by net assets (€1.48 Billion ≈ $1.72 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Almirall S.A. - Cash Flow Conversion Efficiency Trend (2005–2024)

This chart illustrates how Almirall S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Almirall S.A. for a breakdown of total debt and financial obligations.

Almirall S.A. Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Almirall S.A. ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Atlanta Braves Holdings, Inc. Series C Common Stock
NASDAQ:BATRK
0.049x
Shanghai Zhenhua Heavy Industries Co Ltd A
SHG:600320
-0.034x
Hawaiian Electric Industries Inc
NYSE:HE
0.063x
RXO Inc.
NYSE:RXO
0.005x
CLARIANT ADR 1/SF 4
F:CLRS
N/A
Plug Power Inc
NASDAQ:PLUG
-0.060x
Dongguan Yiheda Automation Co. Ltd.
SHE:301029
N/A
Double Medical Technology Inc
SHE:002901
0.060x

Annual Cash Flow Conversion Efficiency for Almirall S.A. (2005–2024)

The table below shows the annual cash flow conversion efficiency of Almirall S.A. from 2005 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Almirall S.A. worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €1.49 Billion
≈ $1.74 Billion
€160.77 Million
≈ $187.95 Million
0.108x +69.08%
2023-12-31 €1.46 Billion
≈ $1.71 Billion
€93.48 Million
≈ $109.29 Million
0.064x -45.69%
2022-12-31 €1.32 Billion
≈ $1.54 Billion
€155.10 Million
≈ $181.33 Million
0.118x -35.32%
2021-12-31 €1.29 Billion
≈ $1.50 Billion
€233.85 Million
≈ $273.40 Million
0.182x +43.80%
2020-12-31 €1.30 Billion
≈ $1.52 Billion
€164.76 Million
≈ $192.63 Million
0.126x -41.38%
2019-12-31 €1.28 Billion
≈ $1.50 Billion
€276.15 Million
≈ $322.84 Million
0.216x +79.51%
2018-12-31 €1.19 Billion
≈ $1.39 Billion
€143.21 Million
≈ $167.43 Million
0.120x +2135.49%
2017-12-31 €1.13 Billion
≈ $1.33 Billion
€6.09 Million
≈ $7.12 Million
0.005x -92.22%
2016-12-31 €1.52 Billion
≈ $1.78 Billion
€105.06 Million
≈ $122.82 Million
0.069x -40.86%
2015-12-31 €1.46 Billion
≈ $1.71 Billion
€170.88 Million
≈ $199.78 Million
0.117x -75.81%
2014-12-31 €1.34 Billion
≈ $1.57 Billion
€646.93 Million
≈ $756.34 Million
0.483x +539.23%
2013-12-31 €888.33 Million
≈ $1.04 Billion
€67.11 Million
≈ $78.46 Million
0.076x -38.11%
2012-12-31 €923.67 Million
≈ $1.08 Billion
€112.75 Million
≈ $131.82 Million
0.122x +4.19%
2011-12-31 €854.71 Million
≈ $999.25 Million
€100.14 Million
≈ $117.07 Million
0.117x -45.02%
2010-12-31 €819.30 Million
≈ $957.85 Million
€174.60 Million
≈ $204.13 Million
0.213x -38.82%
2009-12-31 €751.00 Million
≈ $878.00 Million
€261.60 Million
≈ $305.84 Million
0.348x --
2008-12-31 €0.00
≈ $0.00
€233.10 Million
≈ $272.52 Million
x --
2007-12-31 €573.65 Million
≈ $670.66 Million
€179.03 Million
≈ $209.31 Million
0.312x +45.16%
2006-12-31 €763.21 Million
≈ $892.28 Million
€164.09 Million
≈ $191.84 Million
0.215x +36.46%
2005-12-31 €898.52 Million
≈ $1.05 Billion
€141.57 Million
≈ $165.51 Million
0.158x --

About Almirall S.A.

MC:ALM Spain Drug Manufacturers - Specialty & Generic
Market Cap
$3.16 Billion
€2.70 Billion EUR
Market Cap Rank
#5340 Global
#46 in Spain
Share Price
€12.58
Change (1 day)
+1.29%
52-Week Range
€9.80 - €13.82
All Time High
€16.89
About

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, atopic dermatitis, acne, actinic keratosis, onychomycosis, androgenic alopecia, oncodermatology, and orphan indications, as well as for alimentary tract and metabolism; antiinfecti… Read more